Additional file 3 of Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
posted on 2022-01-22, 04:26authored byYou-Liang Lai, Kai-Hung Wang, Hsing-Pang Hsieh, Wan-Ching Yen
Additional file 3: Table S3. Anti-tumor activity of sorafenib, regorafenib and DBPR114 in sorafenib-refractory HA22T/VGH xenograft tumors on day 40. HA22T/VGH tumor-bearing mice were treated with 40 mg/kg DBPR114 once a week intravenously for 6 weeks or sorafenib and regorafenib at 30 mg/kg once a day, 5 days per week orally for 40 days. Mean ± SEM, n = 8 mice per group. *p < 0.05 vs. vehicle control, **p < 0.05 vs. regorafenib, measured using one-way ANOVA and Bonferroni posttest comparison. Table S4. Anti-tumor activity of sorafenib, regorafenib and DBPR114 in sorafenib-acquired resistant Huh7 xenograft tumors on day 25. Sorafenib-acquired resistant Huh7 tumor-bearing mice were treated with 40 mg/kg DBPR114 once a week intravenously for 3 weeks or sorafenib and regorafenib at 30 mg/kg once a day, 5 days per week orally for 25 days. Mean ± SEM, n = 8 mice per group. *p < 0.05 vs. vehicle control measured using one-way ANOVA and Bonferroni posttest comparison.
Funding
Ministry of Science and Technology, Taiwan The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by Ministry of Education (MOE)